Clinical Trial Update: Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing insulin glargine plus insulin glulisine MDI versus premixed insulin in adults with Type 1 or Type 2 diabetes; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus
• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus

Drugs mentioned

• Insulin Glargine (Lantus) (insulin glargine)
• Insulin glulisine (Apidra) (insulin glulisine)
• premixed insulin therapy (premixed insulin)

Snippet

Sponsor: Sanofi | Conditions: Diabetes Mellitus | Phase 3 | Status: COMPLETED